RefleXion Medical announced today that it entered into a three-system contract with Select Healthcare cancer facility developer.
The multi-year, multi-site contract was agreed upon with the aim of creating new, free-standing treatment centers using the RefleXion X1 platform for treating all stages of cancer with external beam radiotherapy (EBRT).
RefleXion said in a news release that the agreement helps to bring its novel biology-guided radiotherapy (BgRT) — a modality using emissions generated from cancer itself to direct radiotherapy — to Select Healthcare’s local communities so patients with solid tumor cancers can receive care near their home.
BgRT uses emissions from a patient’s cancer cells created by injecting a small amount of a targeting molecule carrying a positron-emitting radioisotope, known as a PET tracer, to guide EBRT. As the PET tracer binds to the tumor cells, it produces emissions that signal the cancer’s location.
The RefleXion X1 machine design integrates PET arcs with a linear accelerator to detect these emissions and then direct radiotherapy to each tumor.
Select Healthcare has led the development and/or acquisition of over 25 healthcare projects in California, Arizona, Nevada, Washington, Idaho, Alaska and the New England area. The first Select Healthcare center offering BgRT is expected to open in late 2023.
“The X1 is the only system to offer breakthrough motion management for moving tumors using biological guidance and anatomic guidance for earlier stage cancers,” Select Healthcare CEO, President and founder Matthew Cutler said in the release. “We envision that this future capability will be attractive to our physician partners because it brings radiotherapy as a new treatment option to patients with late-stage cancer.”
RefleXion designed its X1 machine with BgRT to overcome technical limitations that restrict radiotherapy to one or two tumors to allow radiotherapy to reach more tumors during the same treatment session — even tumors that move due to patient motion caused by things like breathing or digestion.
“We applaud the Select Healthcare vision of bringing advanced cancer care to patients being treated at the community level through the establishment of these new centers,” said Todd Powell, president and CEO of RefleXion. “As we move forward commercializing the X1 and our future release of BgRT, we are proud to count Select Healthcare among our early customers.”